TrialJAMA oncology2023

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial.

Shukui Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.